Recent Updates
Recently added Catalysts
ZYME Positive Sentiment

Zymeworks Announces Participation in Upcoming Investor Conferences

Key Takeaway: Zymeworks Inc. announced its participation in two upcoming investor conferences. The Evercore Healthcare Conference is scheduled for November 30, followed by Citi's Global Healthcare Conference on December 1. Management will hold one-on-one meetings and fireside chats at both events, with webcasts available for interested investors.
Price reaction · baseline $26.04 (2026-11-18 close) · hit pre-market · clean, no other ZYME news in the window
day 0 close · peak
+3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in two major investor conferences
  • Management will engage in one-on-one meetings
  • Live webcasts will be available for broader audience

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+23%
120-day peak, hindsight
Typical move
2.6%
average across 8 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers

Full Press Release Details

VANCOUVER, British Columbia, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced will participate in the following upcoming investor conferences:
• Evercore Healthcare Conference: Management will participate in one-on-one meetings and a fireside chat on November 30 at 2:10 pm Eastern Time (ET) in Miami, FL
• Citi’s 2026 Global Healthcare Conference: Management will participate in one-on-one meetings and a fireside chat on December 1 at 3:40 pm ET in Miami, FL
A live webcast of certain fireside chats will be available in the Investors section of the Zymeworks website at www.zymeworks.com, and a replay will be available following the events.

About Zymeworks Inc.

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. The Company’s asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.
Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric™ platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks’ integrated drug development expertise, enable the Company to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.
For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.

Frequently Asked Questions

When will Zymeworks participate in the investor conferences?

Zymeworks will participate on November 30 and December 1.

Where will the conferences take place?

Both conferences will be held in Miami, FL.

Will there be any live webcasts available?

Yes, live webcasts will be available on Zymeworks' website.

What is Zymeworks known for?

Zymeworks develops novel biotherapeutics and manages healthcare assets.

Last updated: Nov 19, 2026